anti-inflammatoty and immuno-therapy - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.78 [0.43, 1.39]< 10%3 studies (3/-)80.2 %some concernnot evaluable moderatecrucial-
death or transfer to ICU 1.07 [0.73, 1.57]< 10%1 study (1/-)36.6 %highnot evaluable lowcrucial-
deaths 0.87 [0.66, 1.14]< 10%10 studies (10/-)84.3 %highlow lowcrucial-
clinical deterioration 0.58 [0.41, 0.81]< 155%6 studies (6/-)99.9 %highserious lowimportant-
clinical improvement 1.18 [0.94, 1.48]> 10%2 studies (2/-)92.5 %some concernnot evaluable moderateimportant-
clinical improvement (14-day) 8.77 [0.94, 81.67]> 10%1 study (1/-)97.1 %some concernnot evaluable moderateimportant-
clinical improvement (time to event analysis only) 1.15 [0.90, 1.47]> 10%1 study (1/-)86.8 %some concernnot evaluable moderateimportant-
death or ventilation 0.88 [0.54, 1.44]< 171%4 studies (4/-)69.5 %some concernnot evaluable moderateimportant-
hospital discharge 1.16 [0.90, 1.49]> 10%1 study (1/-)87.9 %some concernnot evaluable moderateimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.96 [0.53, 1.73]< 10%2 studies (2/-)55.8 %highnot evaluable lowimportant-
viral clearance 2.00 [0.54, 7.44]> 178%3 studies (3/-)84.8 %some concernnot evaluable moderateimportant-
viral clearance (time to event analysis only) 0.81 [0.56, 1.18]> 10%1 study (1/-)13.7 %some concernnot evaluable moderateimportant-
viral clearance by day 14 10.23 [1.12, 93.35]> 10%1 study (1/-)98.0 %some concernnot evaluable moderateimportant-
viral clearance by day 7 1.21 [1.01, 1.45]> 10%2 studies (2/-)98.1 %highnot evaluable lowimportant-
ICU admission 0.33 [0.07, 1.58]< 10%1 study (1/-)91.7 %lownot evaluable highnon important-

safety endpoints 00

serious adverse events 0.75 [0.47, 1.19]< 10%3 studies (3/-)88.9 %some concernnot evaluable moderateimportant-
adverse events 1.41 [0.74, 2.67]< 10%2 studies (2/-)14.6 %some concernnot evaluable moderatenon important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.